Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.63 |
| ▸ | CNR2 | P34972 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | F7 | P08709 | 1/20 | 0.41 |
| ▸ | F3 | P13726 | 1/20 | 0.41 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3690274 | 0.98 | ALDH1A1 (0.61) | CNR1CNR2ALDH1A1FAAHMAPT | |
| SCHEMBL3687047 | 0.98 | ALDH1A1 (0.61) | CNR1CNR2ALDH1A1FAAHMAPT | |
| SCHEMBL3691941 | 0.89 | ALDH1A1 (0.55) | CNR1CNR2ALDH1A1FAAHMAPT | |
| SCHEMBL3691366 | 0.88 | ALDH1A1 (0.54) | CNR1CNR2ALDH1A1FAAHMAPT | |
| SCHEMBL4456390 | 0.86 | ALDH1A1 (0.53) | CNR1CNR2ALDH1A1FAAHMAPT | |
| SCHEMBL3688962 | 0.86 | ALDH1A1 (0.53) | CNR1CNR2ALDH1A1FAAHMAPT | |
| SCHEMBL3688799 | 0.83 | ALDH1A1 (0.51) | CNR1CNR2ALDH1A1FAAHMAPT | |
| SCHEMBL3696439 | 0.81 | CNR1 (0.54) | CNR1CNR2ALDH1A1FAAHMAPT | |
| SCHEMBL3693540 | 0.81 | ALDH1A1 (0.50) | CNR1CNR2ALDH1A1FAAHMAPT | |
| SCHEMBL3695525 | 0.81 | ALDH1A1 (0.50) | CNR1CNR2ALDH1A1FAAHMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240616-A1 | NOVEL LIPID COMPOUNDS | PRONOVA BIOPHARMA NORGE AS (NO) | 2010-09-23 | — | — | US | disclosed |
| US-20100240616-A1 | NOVEL LIPID COMPOUNDS | PRONOVA BIOPHARMA NORGE AS (NO) | 2010-09-23 | — | — | US | disclosed |
| US-20100240616-A1 | NOVEL LIPID COMPOUNDS | PRONOVA BIOPHARMA NORGE AS (NO) | 2010-09-23 | — | — | US | disclosed |
| EP-2129646-A2 | OMEGA-3 LIPID COMPOUNDS | Pronova Biopharma Norge AS (NO) | 2009-12-09 | — | — | EP | disclosed |
| WO-2008132552-A2 | OMEGA-3 LIPID COMPOUNDS | PRONOVA BIOPHARMA NORGE AS (US) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240616-A1 | NOVEL LIPID COMPOUNDS | ELOVL3, FFAR3, STARD3 | CNR1 258/4885CNR2 131/4885ALDH1A1 2317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.